Compare MMU & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMU | EVO |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.4M | 568.6M |
| IPO Year | 1994 | 2007 |
| Metric | MMU | EVO |
|---|---|---|
| Price | $9.37 | $1.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.24 |
| AVG Volume (30 Days) | ★ 436.2K | 80.7K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.71 | $1.33 |
| 52 Week High | $10.71 | $4.27 |
| Indicator | MMU | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.73 | 46.19 |
| Support Level | $9.30 | $1.50 |
| Resistance Level | $10.33 | $1.97 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 60.44 | 47.50 |
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax, consistent with the preservation of principal. The fund predominantly invests in long-term investment-grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.